HCC
Conditions
Interventions
Experimental group:DEB-TACE Sequential HAIC
Sponsors
Xijing Hospital Affiliated to Air Force Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 78 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in the study and sign the informed consent 2. Age =18 years old, male or female 3. HCC confirmed by histopathology, cytology, or imaging 4. The maximum diameter of the tumor was > 5cm 5. As assessed by MDT (team of surgeons) as unresectable, resection boundaries are unclear and liver reserve function < 30% 6. Confirm at least one measurable intrahepatic target lesion according to RECIST v1.1 criteria 7. Liver function Child-Pugh grade A and B (within 8 points) without cirrhosis or cirrhosis 8. The physical status score of the United States Eastern Cancer Consortium (ECOG) was less than 1 point 9. Life expectancy is over 3 months
Exclusion criteria
Exclusion criteria: 1. Cancer thrombus accompanied by main portal vein or involving primary branch of bilateral portal vein and no major outflow tract; 2. Patients with diffuse liver cancer; 3. Hepatic decompensation, including: massive ascites, esophageal and gastric variceal bleeding, hepatic encephalopathy; 4. Organ (heart, kidney) dysfunction, unable to tolerate TACE or HAIC treatment; 5. History of other malignant tumors; 6. Have an active infection (including tuberculosis) that requires systematic treatment, other than HCV or HBV; 7. Subjects who have received allogeneic tissue/solid organ transplants; 8. People with HIV history; 9.30 days of gastrointestinal bleeding, or combined with = grade 3 gastrointestinal or non-gastrointestinal fistula; 10.Is currently participating in or has previously participated in an investigational drug study, or has used an investigational device within 4 weeks prior to initial dosing of the investigational drug; Medical history or evidence of disease that may interfere with the test results, prevent the subject from fully participating in the study, abnormal treatment or laboratory values, or the investigator believes that participation in the study is not in the subject's best interest;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival rate;Progression-free survival;Therapeutic effective rate; | — |
Countries
China
Contacts
Public ContactAn rui
Xijing Hospital Affiliated to Air Force Medical University
Outcome results
None listed